Gabriel CapellÃ¡ Munar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4631121/publications.pdf

Version: 2024-02-01

325 papers	19,180 citations	15504 65 h-index	15732 125 g-index
333 all docs	333 docs citations	333 times ranked	24215 citing authors

#	Article	IF	Citations
1	Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2022, 20, 611-621.e9.	4.4	17
2	Solving the enigma of POLD1 p.V295M as a potential cause of increased cancer risk. European Journal of Human Genetics, 2022, 30, 485-489.	2.8	2
3	Variants of uncertain significance (VUS) in cancer predisposing genes: What are we learning from multigene panels?. European Journal of Medical Genetics, 2022, 65, 104400.	1.3	4
4	Potential Involvement of NSD1, KRT24 and ACACA in the Genetic Predisposition to Colorectal Cancer. Cancers, 2022, 14, 699.	3.7	0
5	Mosaicism in PTENâ€"new case and comment on the literature. European Journal of Human Genetics, 2022, 30, 641-644.	2.8	6
6	Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. , 2022, 10, e003255.		26
7	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromesâ€“ a collaborative multicentre endeavour within the project Solve-RD. European Journal of Medical Genetics, 2022, 65, 104475.	1.3	2
8	Splicing analyses for variants in MMR genes: best practice recommendations from the European Mismatch Repair Working Group. European Journal of Human Genetics, 2022, 30, 1051-1059.	2.8	7
9	An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide) Tj ETQq1 1 0.784314 rgBT /Overloc	2.5	6
10	Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum. International Journal of Cancer, 2021, 148, 512-513.	5.1	9
11	The â€œunnaturalâ€•history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance. International Journal of Cancer, 2021, 148, 800-811.	5.1	55
12	TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes. Gut, 2021, 70, 1139-1146.	12.1	10
13	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	2.4	28
14	A Collaborative Effort to Define Classification Criteria forATMVariants in Hereditary Cancer Patients. Clinical Chemistry, 2021, 67, 518-533.	3.2	14
15	Characteristics of Adrenocortical Carcinoma Associated With Lynch Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 318-325.	3.6	20
16	Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. Modern Pathology, 2021, 34, 994-1007.	5.5	19
17	Duodenal Adenomas and Cancer in MUTYH-associated Polyposis: An International Cohort Study. Gastroenterology, 2021, 160, 952-954.e4.	1.3	20
18	BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort. Genes, 2021, 12, 150.	2.4	11

#	Article	IF	Citations
19	Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11. Journal of Controlled Release, 2021, 332, 517-528.	9.9	14
20	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133.	2.8	11
21	A genetic variant in telomerase reverse transcriptase (TERT) modifies cancer risk in Lynch syndrome patients harbouring pathogenic MSH2 variants. Scientific Reports, 2021, 11, 11401.	3.3	6
22	CNVfilteR: an R/Bioconductor package to identify false positives produced by germline NGS CNV detection tools. Bioinformatics, 2021, 37, 4227-4229.	4.1	1
23	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
24	KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer. Oncogene, 2021, 40, 5730-5740.	5.9	5
25	Non-Lynch Familial and Early-Onset Colorectal Cancer Explained by Accumulation of Low-Risk Genetic Variants. Cancers, 2021, 13, 3857.	3.7	8
26	Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19. Frontiers in Immunology, 2021, 12, 719115.	4.8	76
27	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	10.7	58
28	Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancerâ€“Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. Journal of Molecular Diagnostics, 2021, 23, 1452-1459.	2.8	10
29	VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. , 2021, 9, e003254.		31
30	RNA assay identifies a previous misclassification of BARD1 c.1977A>G variant. Scientific Reports, 2021, 11, 22948.	3.3	0
31	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	2.4	365
32	Validation of an inÂVitro Mismatch Repair Assay Used in the Functional Characterization of Mismatch Repair Variants. Journal of Molecular Diagnostics, 2020, 22, 376-385.	2.8	5
33	Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals. Cancers, 2020, 12, 1799.	3.7	15
34	Screening of CNVs using NGS data improves mutation detection yield and decreases costs in genetic testing for hereditary cancer. Journal of Medical Genetics, 2020, , jmedgenet-2020-107366.	3.2	3
35	Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals. Cancers, 2020, 12, 3419.	3.7	11
36	Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092957.	3.2	5

#	Article	IF	Citations
37	Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. Journal of Clinical Medicine, 2020, 9, 2290.	2.4	12
38	Role of POLE and POLD1 in familial cancer. Genetics in Medicine, 2020, 22, 2089-2100.	2.4	76
39	ERCC3, a new ovarian cancer susceptibility gene?. European Journal of Cancer, 2020, 141, 1-8.	2.8	8
40	Comprehensive analysis and ACMGâ€based classification of CHEK2 variants in hereditary cancer patients. Human Mutation, 2020, 41, 2128-2142.	2.5	10
41	Molecular Nodal Restaging Based on CEACAM5, FGFR2b and PTPN11 Expression Adds No Relevant Clinical Information in Resected Non-Small Cell Lung Cancer. Journal of Investigative Surgery, 2020, , 1-10.	1.3	2
42	High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers. Journal of Medical Genetics, 2020, 57, 269-273.	3.2	20
43	Evaluation of CNV detection tools for NGS panel data in genetic diagnostics. European Journal of Human Genetics, 2020, 28, 1645-1655.	2.8	67
44	Germline Mutations in FAF1 Are Associated With Hereditary Colorectal Cancer. Gastroenterology, 2020, 159, 227-240.e7.	1.3	18
45	Dominantly Inherited Hereditary Nonpolyposis Colorectal Cancer Not Caused by MMR Genes. Journal of Clinical Medicine, 2020, 9, 1954.	2.4	15
46	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. Journal of Thoracic Oncology, 2020, 15, 1232-1239.	1.1	29
47	Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients. Cancers, 2020, 12, 829.	3.7	41
48	Colorectal cancer genetic variants are also associated with serrated polyposis syndrome susceptibility. Journal of Medical Genetics, 2020, 57, 677-682.	3.2	11
49	Candidate genes for hereditary colorectal cancer: Mutational screening and systematic review. Human Mutation, 2020, 41, 1563-1576.	2.5	29
50	Improving Genetic Testing in Hereditary Cancer by RNA Analysis. Journal of Molecular Diagnostics, 2020, 22, 1453-1468.	2.8	9
51	Expression and Role of MicroRNAs from the miR-200 Family in the Tumor Formation and Metastatic Propensity of Pancreatic Cancer. Molecular Therapy - Nucleic Acids, 2019, 17, 491-503.	5.1	54
52	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 28.	1.5	27
53	Germline variation in O6-methylguanine-DNA methyltransferase (MGMT) as cause of hereditary colorectal cancer. Cancer Letters, 2019, 447, 86-92.	7.2	12
54	An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genetics in Medicine, 2019, 21, 2706-2712.	2.4	11

#	Article	IF	Citations
55	NTHL1 biallelic mutations seldom cause colorectal cancer, serrated polyposis or a multi-tumor phenotype, in absence of colorectal adenomas. Scientific Reports, 2019, 9, 9020.	3.3	23
56	Contribution to colonic polyposis of recently proposed predisposing genes and assessment of the prevalence of NTHL1 â€•and MSH3 â€associated polyposes. Human Mutation, 2019, 40, 1910-1923.	2.5	24
57	Defining a mutational signature for endometrial cancer screening and early detection. Cancer Epidemiology, 2019, 61, 129-132.	1.9	7
58	New perspectives on screening and early detection of endometrial cancer. International Journal of Cancer, 2019, 145, 3194-3206.	5.1	58
59	The Apparent Genetic Anticipation in PMS2-Associated Lynch Syndrome Families Is Explained by Birth-cohort Effect. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1010-1014.	2.5	6
60	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	1.5	42
61	Noncanonical TGFÎ² Pathway Relieves the Blockade of IL1Î²/TGFÎ²-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer. Clinical Cancer Research, 2019, 25, 4466-4479.	7.0	32
62	Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. International Journal of Cancer, 2019, 145, 2682-2691.	5.1	30
63	Approaches to functionally validate candidate genetic variants involved in colorectal cancer predisposition. Molecular Aspects of Medicine, 2019, 69, 27-40.	6.4	5
64	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype. Cancer Cell, 2019, 35, 256-266.e5.	16.8	123
65	Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation. Clinical Epigenetics, 2019, 11, 171.	4.1	7
66	Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. Scientific Reports, 2019, 9, 18555.	3.3	13
67	Does multilocus inherited neoplasia alleles syndrome have severe clinical expression?. Journal of Medical Genetics, 2019, 56, 521-525.	3.2	11
68	Are women with pathogenic variants in PMS2 and MSH6 really at high lifetime risk of breast cancer?. Genetics in Medicine, 2019, 21, 1878-1879.	2.4	6
69	NovelPOLEpathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures. Human Mutation, 2019, 40, 36-41.	2.5	21
70	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. Familial Cancer, 2019, 18, 281-284.	1.9	17
71	Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent. Clinical Cancer Research, 2018, 24, 3755-3766.	7.0	17
72	Evidence suggests that germline RNF43 mutations are a rare cause of serrated polyposis. Gut, 2018, 67, 2230-2232.	12.1	48

#	Article	IF	Citations
73	Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316.	12.1	410
74	Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer. Gastroenterology, 2018, 154, 181-194.e20.	1.3	32
75	Cancer Risks for PMS2-Associated Lynch Syndrome. Journal of Clinical Oncology, 2018, 36, 2961-2968.	1.6	147
76	Primary constitutional MLH1 epimutations: a focal epigenetic event. British Journal of Cancer, 2018, 119, 978-987.	6.4	22
77	Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?. Frontiers in Genetics, 2018, 9, 366.	2.3	53
78	Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are infrequent in familial colorectal cancer and polyposis. Molecular Cancer, 2018, 17, 23.	19.2	19
79	The Molecular Basis of Lynch-like Syndrome. , 2018, , 21-41.		2
80	New Methylation Biomarker Panel for Early Diagnosis of Dysplasia or Cancer in High-Risk Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2018, 24, 2555-2564.	1.9	23
81	Germline variation in the oxidative DNA repair genes NUDT1 and OGG1 is not associated with hereditary colorectal cancer or polyposis. Human Mutation, 2018, 39, 1214-1225.	2.5	10
82	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 2017, 66, 464-472.	12.1	411
83	Elucidating the clinical significance of two PMS2 missense variants coexisting in a family fulfilling hereditary cancer criteria. Familial Cancer, 2017, 16, 501-507.	1.9	3
84	Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 2017, 16, 1999-2007.	4.1	12
85	Elucidating the molecular basis of MSH2â€deficient tumors by combined germline and somatic analysis. International Journal of Cancer, 2017, 141, 1365-1380.	5.1	26
86	Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut, 2017, 66, 1657-1664.	12.1	127
87	Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort: A nested caseâ€control study. International Journal of Cancer, 2017, 140, 1727-1735.	5.1	23
88	Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer. Scientific Reports, 2017, 7, 37984.	3.3	35
89	A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. Scientific Reports, 2017, 7, 39348.	3.3	45
90	Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis. Clinical Cancer Research, 2017, 23, 5936-5947.	7.0	25

#	Article	IF	Citations
91	Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. British Journal of Cancer, 2017, 117, 421-431.	6.4	125
92	Delineating the Phenotypic Spectrum of the NTHL1-AssociatedÂPolyposis. Clinical Gastroenterology and Hepatology, 2017, 15, 461-462.	4.4	41
93	Candidate predisposing germline copy number variants in early onset colorectal cancer patients. Clinical and Translational Oncology, 2017, 19, 625-632.	2.4	5
94	Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. Hereditary Cancer in Clinical Practice, 2017, 15, 18.	1.5	49
95	Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells. Oncotarget, 2016, 7, 59766-59780.	1.8	42
96	Identification of a founder <scp>BRCA1</scp> mutation in the Moroccan population. Clinical Genetics, 2016, 90, 361-365.	2.0	13
97	Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prevention Research, 2016, 9, 417-427.	1.5	65
98	Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Molecular Cancer Therapeutics, 2016, 15, 1106-1112.	4.1	15
99	APC promoter is frequently methylated in pancreatic juice of patients with pancreatic carcinomas or periampullary tumors. Oncology Letters, 2016, 12, 2210-2216.	1.8	13
100	Scarce evidence of the causal role of germline mutations in UNC5C in hereditary colorectal cancer and polyposis. Scientific Reports, 2016, 6, 20697.	3.3	9
101	Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA. Breast Cancer Research and Treatment, 2016, 155, 253-260.	2.5	6
102	POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genetics in Medicine, 2016, 18, 325-332.	2.4	209
103	The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers. Genetics in Medicine, 2016, 18, 405-409.	2.4	15
104	Quantification of Unmethylated Alu (QUAlu): a tool to assess global hypomethylation in routine clinical samples. Oncotarget, 2016, 7, 10536-10546.	1.8	14
105	Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Molecular Medicine, 2015, 7, 608-627.	6.9	36
106	Tumor growth delay by adjuvant alternating electric fields which appears non-thermally mediated. Bioelectrochemistry, 2015, 105, 16-24.	4.6	9
107	Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors. Oncologist, 2015, 20, 127-133.	3.7	109
108	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221

#	Article	IF	Citations
109	Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair. Gastroenterology, 2015, 149, 563-566.	1.3	94
110	AMER1 Is a Frequently Mutated Gene in Colorectal Cancerâ€"Letter. Clinical Cancer Research, 2015, 21, 4985-4985.	7.0	4
111	Lynch Syndrome Caused by Germline PMS2 Mutations: Delineating the Cancer Risk. Journal of Clinical Oncology, 2015, 33, 319-325.	1.6	177
112	Exome sequencing identifiesMUTYHmutations in a family with colorectal cancer and an atypical phenotype. Gut, 2015, 64, 355-356.	12.1	14
113	Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC): Interim analysis of a Spanish cohort.. Journal of Clinical Oncology, 2015, 33, e14613-e14613.	1.6	0
114	Abstract 1087: Genomic analysis reveals evidence of clonality in premalignant colonic polyps. , 2015, , .		0
115	Abstract 4806: Characterizing the genomic landscape of premalignant colorectal polyps using next-generation sequencing. , 2015, , .		0
116	Abstract 2396: Hampering the crosstalk between fibroblasts and tumor cells reveals the need for blocking both canonical and non-canonical TGFÎ² pathways. , 2015, , .		0
117	A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer. Oncotarget, 2014, 5, 6437-6452.	1.8	30
118	Unsupervised analyses reveal molecular subtypes associated to prognosis and response to therapy in colorectal cancer. Colorectal Cancer, 2014, 3, 277-288.	0.8	2
119	Paracrine Network: Another Step in the Complexity of Resistance to EGFR Blockade?. Clinical Cancer Research, 2014, 20, 6227-6229.	7.0	4
120	Phosphorylation at Ser-181 of Oncogenic KRAS Is Required for Tumor Growth. Cancer Research, 2014, 74, 1190-1199.	0.9	54
121	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
122	KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. Journal of Thoracic Oncology, 2014, 9, 1513-1522.	1.1	108
123	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelialâ€toâ€mesenchymal transition. International Journal of Cancer, 2014, 134, 552-562.	5.1	286
124	Genetic variants in theIL1Agene region contribute to intestinal-type gastric carcinoma susceptibility in European populations. International Journal of Cancer, 2014, 135, 1343-1355.	5.1	11
125	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	1.9	195
126	ICO Amplicon NGS Data Analysis: A Web Tool for Variant Detection in Common High-Risk Hereditary Cancer Genes Analyzed by Amplicon GS Junior Next-Generation Sequencing. Human Mutation, 2014, 35, 271-277.	2.5	2

#	Article	IF	Citations
127	Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nature Genetics, 2014, 46, 107-115.	21.4	410
128	GALNT12is Not a Major Contributor of Familial Colorectal Cancer Type X. Human Mutation, 2014, 35, 50-52.	2.5	22
129	Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. Gastroenterology, 2014, 147, 882-892.e8.	1.3	56
130	New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Human Molecular Genetics, 2014, 23, 3506-3512.	2.9	135
131	Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. European Journal of Cancer, 2014, 50, 2241-2250.	2.8	66
132	Little evidence for association between the TGFBR1*6A variant and colorectal cancer: a family-based association study on non-syndromic family members from Australia and Spain. BMC Cancer, 2014, 14, 475.	2.6	1
133	Comprehensive molecular characterisation of hereditary non-polyposis colorectal tumours with mismatch repair proficiency. European Journal of Cancer, 2014, 50, 1964-1972.	2.8	8
134	Identification of a founder EPCAM deletion in Spanish Lynch syndrome families. Clinical Genetics, 2014, 85, 260-266.	2.0	12
135	Longer Telomeres Are Associated with Cancer Risk in MMR-Proficient Hereditary Non-Polyposis Colorectal Cancer. PLoS ONE, 2014, 9, e86063.	2.5	13
136	Relationship between methylation and colonic inflammation in inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 10591.	3.3	11
137	Novel Methylation Panel for the Early Detection of Neoplasia in High-risk Ulcerative Colitis and CrohnÊ¼s Colitis Patients. Inflammatory Bowel Diseases, 2013, 19, 165-173.	1.9	33
138	An association between the PTGS2 rs5275 polymorphism and colorectal cancer risk in families with inherited non-syndromic predisposition. European Journal of Human Genetics, 2013, 21, 1389-1395.	2.8	6
139	The impact of KRAS mutations on VEGF-A production and tumour vascular network. BMC Cancer, 2013, 13, 125.	2.6	25
140	Genetic variant in the telomerase gene modifies cancer risk in Lynch syndrome. European Journal of Human Genetics, 2013, 21, 511-516.	2.8	20
141	Refining the role ofpms2in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants. Journal of Medical Genetics, 2013, 50, 552-563.	3.2	47
142	Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. European Journal of Human Genetics, 2013, 21, 864-870.	2.8	94
143	Genetic and epigenetic markers in the evaluation of pancreatic masses. Journal of Clinical Pathology, 2013, 66, 192-197.	2.0	18
144	Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut, 2013, 62, 812-823.	12.1	630

#	Article	IF	Citations
145	Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification. Human Pathology, 2013, 44, 412-416.	2.0	20
146	A combined oncogenic pathway signature ofBRAF,KRASandPI3KCAmutation improves colorectal cancer classification and cetuximab treatment prediction. Gut, 2013, 62, 540-549.	12.1	121
147	Metronomic chemotherapy following the maximum tolerated dose is an effective antiâ€tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. International Journal of Cancer, 2013, 133, 2464-2472.	5.1	76
148	Nanofluidic Digital PCR for Improved Selection of Metastatic Colorectal Cancer Patients to Anti-EGFR Therapies. Annals of Oncology, 2013, 24, iv15-iv16.	1.2	0
149	Molecular markers in colorectal cancer: clinical relevance in stage II colon cancer. Colorectal Cancer, 2013, 2, 243-263.	0.8	4
150	Grape antioxidant dietary fiber inhibits intestinal polyposis in Apc Min/+ mice: relation to cell cycle and immune response. Carcinogenesis, 2013, 34, 1881-1888.	2.8	38
151	DNA Methylation Biomarkers for Noninvasive Diagnosis of Colorectal Cancer. Cancer Prevention Research, 2013, 6, 656-665.	1.5	107
152	Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma. Clinical Cancer Research, 2013, 19, 6842-6852.	7.0	62
153	Telomere Length and Genetic Anticipation in Lynch Syndrome. PLoS ONE, 2013, 8, e61286.	2.5	21
154	Functional and Structural Analysis of C-Terminal BRCA1 Missense Variants. PLoS ONE, 2013, 8, e61302.	2.5	16
155	Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT).. Journal of Clinical Oncology, 2013, 31, 333-333.	1.6	0
156	Evidence of linkage to chromosomes 10p15.3â€“p15.1, 14q24.3â€“q31.1 and 9q33.3â€“q34.3 in non-syndromic colorectal cancer families. European Journal of Human Genetics, 2012, 20, 91-96.	2.8	11
157	A DNA methylation fingerprint of 1628 human samples. Genome Research, 2012, 22, 407-419.	5.5	341
158	MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. European Journal of Human Genetics, 2012, 20, 762-768.	2.8	76
159	MLH1 methylation screening is effective in identifying epimutation carriers. European Journal of Human Genetics, 2012, 20, 1256-1264.	2.8	36
160	Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer. Clinical Cancer Research, 2012, 18, 5399-5411.	7.0	86
161	Genetic variation in MUC1, MUC2 and MUC6 genes and evolution of gastric cancer precursor lesions in a long-term follow-up in a high-risk area in Spain. Carcinogenesis, 2012, 33, 1072-1080.	2.8	22
162	An optimized predictor panel for colorectal cancer diagnosis based on the combination of tumor-associated antigens obtained from protein and phage microarrays. Journal of Proteomics, 2012, 75, 4647-4655.	2.4	50

#	Article	IF	Citations
163	Helicobacter pylori vacA Intermediate Region Genotyping and Progression of Gastric Preneoplastic Lesions. American Journal of Gastroenterology, 2012, 107, 145-146.	0.4	13
164	Nanofluidic Digital PCR for KRAS Mutation Detection and Quantification in Gastrointestinal Cancer. Clinical Chemistry, 2012, 58, 1332-1341.	3.2	52
165	Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. Molecular Carcinogenesis, 2012, 51, 746-753.	2.7	53
166	Comprehensive functional assessment ofMLH1variants of unknown significance. Human Mutation, 2012, 33, 1576-1588.	2.5	30
167	Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes. Breast Cancer Research and Treatment, 2012, 132, 979-992.	2.5	20
168	Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families. BMC Cancer, 2012, 12, 84.	2.6	14
169	Clinical Value of Prognosis Gene Expression Signatures in Colorectal Cancer: A Systematic Review. PLoS ONE, 2012, 7, e48877.	2.5	79
170	Development and validation of a genomic signature to identify colorectal cancer patients with microsatellite instability.. Journal of Clinical Oncology, 2012, 30, 466-466.	1.6	0
171	Abstract 4445: Defining a pipeline to use next generation sequencing for genetic testing in hereditary cancer. , 2012, , .		0
172	Mutational load distribution analysis of colorectal and pancreatic carcinoma by next generation sequencing platform.. Journal of Clinical Oncology, 2012, 30, 57-57.	1.6	0
173	Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 17-24.	1.6	487
174	Helicobacter pylori cagA and vacA Genotypes as Predictors of Progression of Gastric Preneoplastic Lesions: A Long-Term Follow-Up in a High-Risk Area in Spain. American Journal of Gastroenterology, 2011, 106, 867-874.	0.4	111
175	No association between germline allele-specific expression of TGFBR1 and colorectal cancer risk in Caucasian and Ashkenazi populations. British Journal of Cancer, 2011, 104, 735-740.	6.4	8
176	Identification of a new complex rearrangement affecting exon 20 of BRCA1. Breast Cancer Research and Treatment, 2011, 130, 341-344.	2.5	3
177	The use of caspase inhibitors in pulsed-field gel electrophoresis may improve the estimation of radiation-induced DNA repair and apoptosis. Radiation Oncology, 2011, 6, 6.	2.7	5
178	Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH. Human Mutation, 2011, 32, 78-90.	2.5	66
179	A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1-splice mutation and the presence of a complex mosaicism. Human Mutation, 2011, 32, 705-709.	2.5	18
180	Surgical management of the duodenal manifestations of familial adenomatous polyposis. British Journal of Surgery, 2011, 98, 480-484.	0.3	36

#	Article	IF	Citations
181	Identification of MST1/STK4 and SULF1 Proteins as Autoantibody Targets for the Diagnosis of Colorectal Cancer by Using Phage Microarrays. Molecular and Cellular Proteomics, 2011, 10, M110.001784.	3.8	58
182	Characterization of New Founder Alu-Mediated Rearrangements in MSH2 Gene Associated with a Lynch Syndrome Phenotype. Cancer Prevention Research, 2011, 4, 1546-1555.	1.5	17
183	Reply: Allelic imbalance of TGFBR1 is not a major contributor to the genetic predisposition to colorectal cancer. British Journal of Cancer, 2011, 104, 1519-1520.	6.4	0
184	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	5.6	91
185	Clinical and genetic characterization of classical forms of familial adenomatous polyposis: a Spanish population study. Annals of Oncology, 2011, 22, 903-909.	1.2	39
186	APC Yin-Yang haplotype associated with colorectal cancer risk. Experimental and Therapeutic Medicine, 2010, 1, 879-883.	1.8	0
187	Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes. Breast Cancer Research and Treatment, 2010, 122, 733-743.	2.5	34
188	Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes and Control, 2010, 21, 737-743.	1.8	60
189	Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Familial Cancer, 2010, 9, 109-115.	1.9	103
190	Detection of genetic alterations in hereditary colorectal cancer screeningâ˜†. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 693, 19-31.	1.0	29
191	Gastric cancer occurrence in preneoplastic lesions: A longâ€term followâ€up in a highâ€risk area in Spain. International Journal of Cancer, 2010, 127, 2654-2660.	5.1	71
192	Oncogenic KRAS is not necessary for Wnt signalling activation in APCâ€associated FAP adenomas. Journal of Pathology, 2010, 221, 57-67.	4.5	24
193	A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. British Journal of Cancer, 2010, 103, 1875-1884.	6.4	107
194	Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment. European Journal of Human Genetics, 2010, 18, 614-617.	2.8	16
195	Founder effect of a pathogenic MSH2 mutation identified in Spanish families with Lynch syndrome. Clinical Genetics, 2010, 78, 186-190.	2.0	11
196	Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy. Oncologist, 2010, 15, 976-986.	3.7	30
197	Filamin B Plays a Key Role in Vascular Endothelial Growth Factor-induced Endothelial Cell Motility through Its Interaction with Rac-1 and Vav-2. Journal of Biological Chemistry, 2010, 285, 10748-10760.	3.4	75
198	MLH1 Founder Mutations with Moderate Penetrance in Spanish Lynch Syndrome Families. Cancer Research, 2010, 70, 7379-7391.	0.9	29

#	Article	IF	Citations
199	Vitamins B2 and B6 and Genetic Polymorphisms Related to One-Carbon Metabolism as Risk Factors for Gastric Adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 28-38.	2.5	39
200	TACC3-TSC2 maintains nuclear envelope structure and controls cell division. Cell Cycle, 2010, 9, 1143-1155.	2.6	46
201	Smoking, Gender, and Ethnicity Predict Somatic BRAF Mutations in Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 838-843.	2.5	64
202	Novel Methylation Panel for the Early Detection of Colorectal Tumors in Stool DNA. Clinical Colorectal Cancer, 2010, 9, 168-176.	2.3	59
203	Allele-Specific Expression of APC in Adenomatous Polyposis Families. Gastroenterology, 2010, 139, 439-447.e1.	1.3	34
204	Simultaneous Genotyping of GSTT1 and GSTM1 Null Polymorphisms by Melting Curve Analysis in Presence of SYBR Green I. Journal of Molecular Diagnostics, 2010, 12, 300-304.	2.8	17
205	Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut, 2010, 59, 975-986.	12.1	635
206	Abstract 5756: The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. , 2010, , .		0
207	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Research, 2009, 19, 438-451.	5.5	218
208	Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. British Journal of Cancer, 2009, 100, 1534-1539.	6.4	66
209	Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6315-6320.	7.1	338
210	Genetic Inactivation of ADAMTS15 Metalloprotease in Human Colorectal Cancer. Cancer Research, 2009, 69, 4926-4934.	0.9	71
211	Aromatic DNA adducts and polymorphisms in metabolic genes in healthy adults: findings from the EPIC-Spain cohort. Carcinogenesis, 2009, 30, 968-976.	2.8	28
212	Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors. Clinical Cancer Research, 2009, 15, 3384-3395.	7.0	57
213	TheADAMTS12metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer. Journal of Cell Science, 2009, 122, 2906-2913.	2.0	76
214	Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Human Mutation, 2009, 30, 454-462.	2.5	46
215	An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. International Journal of Cancer, 2009, 125, 257-263.	5.1	44
216	High risk of endometrial cancer in colorectal cancer kindred is pathognomonic for MMR-mutation carriers. Familial Cancer, 2009, 8, 145-151.	1.9	11

#	Article	IF	Citations
217	A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nature Genetics, 2009, 41, 365-370.	21.4	355
218	Biological Convergence of Cancer Signatures. PLoS ONE, 2009, 4, e4544.	2.5	20
219	Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer. Breast Cancer Research and Treatment, 2008, 109, 463-470.	2.5	8
220	Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer. International Journal of Colorectal Disease, 2008, 23, 21-27.	2.2	23
221	Germline hypermethylation of the APC promoter is not a frequent cause of familial adenomatous polyposis in APC/MUTYH mutation negative families. International Journal of Cancer, 2008, 122, 1422-1425.	5.1	15
222	Nonâ€Hodgkin lymphoma related to hereditary nonpolyposis colorectal cancer in a patient with a novel heterozygous complex deletion in the MSH2 gene. Genes Chromosomes and Cancer, 2008, 47, 326-332.	2.8	18
223	Inhibitory Effect of Cetuximab on Radiation-resistant A431 Cells: An In Vivo Model. International Journal of Radiation Oncology Biology Physics, 2008, 72, S376.	0.8	0
224	PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. British Journal of Cancer, 2008, 99, 1718-1725.	6.4	32
225	Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nature Genetics, 2008, 40, 631-637.	21.4	542
226	Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility. BMC Genomics, 2008, 9, 12.	2.8	27
227	CLEAR-test: Combining inference for differential expression and variability in microarray data analysis. Journal of Biomedical Informatics, 2008, 41, 33-45.	4.3	8
228	Functional Characterization of the Novel APC N1026S Variant Associated With Attenuated Familial Adenomatous Polyposis. Gastroenterology, 2008, 134, 56-64.	1.3	20
229	DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. International Journal of Epidemiology, 2008, 37, 1316-1325.	1.9	68
230	Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut, 2008, 57, 704-713.	12.1	591
231	Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Molecular Cancer Therapeutics, 2008, 7, 638-647.	4.1	61
232	Detection of APC Gene Deletions Using Quantitative Multiplex PCR of Short Fluorescent Fragments. Clinical Chemistry, 2008, 54, 1132-1140.	3.2	26
233	Mutational load distribution analysis yields metrics reflecting genetic instability during pancreatic carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4306-4311.	7.1	12
234	Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Annals of Oncology, 2008, 19, 1894-1902.	1.2	105

#	Article	IF	Citations
235	Genomic Instability, DNA Repair Pathways and Cancer. , 2008, , 269-279.		1
236	Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients. International Journal of Oncology, 2007, 30, 1099.	3.3	11
237	Aberrant Cytoplasmic Localization of N-CoR in Colorectal Tumors. Cell Cycle, 2007, 6, 1748-1752.	2.6	35
238	The Association of Gastric Cancer Risk with Plasma Folate, Cobalamin, and Methylenetetrahydrofolate Reductase Polymorphisms in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2416-2424.	2.5	60
239	Nuclear IKK activity leads to dysregulated Notch-dependent gene expression in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 276-281.	7.1	134
240	Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis, 2007, 28, 1241-1246.	2.8	34
241	Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. European Journal of Cancer, 2007, 43, 762-768.	2.8	46
242	Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). Journal of Medical Genetics, 2007, 44, 353-362.	3.2	461
243	Integrative analysis of a cancer somatic mutome. Molecular Cancer, 2007, 6, 13.	19.2	28
244	APC Inactivation Associates With Abnormal Mitosis Completion and Concomitant BUB1B/MAD2L1 Up-Regulation. Gastroenterology, 2007, 132, 2448-2458.	1.3	36
245	Molecular characterization of a t(9;12)(p21;q13) balanced chromosome translocation in combination with integrative genomics analysis identifiesC9orf14as a candidate tumor-suppressor. Genes Chromosomes and Cancer, 2007, 46, 155-162.	2.8	10
246	Tumor LOH analysis provides reliable linkage information for prenatal genetic testing of sporadic NF1 patients. Genes Chromosomes and Cancer, 2007, 46, 820-827.	2.8	5
247	Evidence for systems-level molecular mechanisms of tumorigenesis. BMC Genomics, 2007, 8, 185.	2.8	31
248	Deletion of VAI and VAII RNA Genes in the Design of Oncolytic Adenoviruses. Human Gene Therapy, 2006, 17, 929-940.	2.7	31
249	Polymorphisms in Metabolic Genes Related to Tobacco Smoke and the Risk of Gastric Cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2427-2434.	2.5	57
250	The Wnt pathway is active in a small subset of pancreas cancer cell lines. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 73-79.	3.8	13
251	Polymorphisms within inflammatory genes and colorectal cancer. Journal of Negative Results in BioMedicine, 2006, 5, 15.	1.4	59
252	K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis, 2006, 27, 2190-2200.	2.8	58

#	Article	IF	Citations
253	Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment. Journal of Clinical Oncology, 2006, 24, 1603-1611.	1.6	121
254	Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Annals of Oncology, 2006, 17, 842-847.	1.2	92
255	Genetic instability and divergence of clonal populations in colon cancer cells in vitro. Journal of Cell Science, 2006, 119, 1477-1482.	2.0	47
256	Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. Journal of Medical Genetics, 2006, 44, 75-80.	3.2	25
257	Polymorphisms in Genes of Nucleotide and Base Excision Repair: Risk and Prognosis of Colorectal Cancer. Clinical Cancer Research, 2006, 12, 2101-2108.	7.0	227
258	EPHB4 and Survival of Colorectal Cancer Patients. Cancer Research, 2006, 66, 8943-8948.	0.9	80
259	No Association between Polymorphisms in CYP2E1, GSTM1, NAT1, NAT2 and the Risk of Gastric Adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1043-1045.	2.5	25
260	Chromosomal Instability Correlates with Genome-wide DNA Demethylation in Human Primary Colorectal Cancers. Cancer Research, 2006, 66, 8462-9468.	0.9	286
261	Deletion of VAI and VAII RNA Genes in the Design of Oncolytic Adenoviruses. Human Gene Therapy, 2006, .	2.7	0
262	A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenetics and Genomics, 2005, 15, 535-546.	1.5	135
263	MTAP homozygous deletion: An achilles heel of human cancers ready for clinical use?. Cancer Biology and Therapy, 2005, 4, 347-347.	3.4	4
264	Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy. Oncogene, 2005, 24, 7320-7326.	5.9	50
265	Founder mutation in familial adenomatous polyposis (FAP) in the Balearic Islands. Cancer Genetics and Cytogenetics, 2005, 158, 70-74.	1.0	15
266	Low levels of microsatellite instability characterize MLH1 and MSH2 HNPCC carriers before tumor diagnosis. Human Molecular Genetics, 2005, 14, 235-239.	2.9	72
267	K-ras Codon-Specific Mutations Produce Distinctive Metabolic Phenotypes in Human Fibroblasts. Cancer Research, 2005, 65, 5512-5515.	0.9	110
268	Validation of RNA Arbitrarily Primed PCR Probes Hybridized to Glass cDNA Microarrays: Application to the Analysis of Limited Samples. Clinical Chemistry, 2005, 51, 93-101.	3.2	3
269	Polymorphisms of the Dopamine Receptor Gene DRD2 and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1633-1638.	2.5	41
270	Is fecal DNA testing superior to fecal occult-blood testing for colorectal cancer screening?. Nature Clinical Practice Oncology, 2005, 2, 234-235.	4.3	3

#	Article	IF	Citations
271	Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Human Molecular Genetics, 2005, 14, 319-326.	2.9	138
272	Genomic determinants of prognosis in colorectal cancer. Cancer Letters, 2005, 221, 1-9.	7.2	19
273	Enhancement of Gemcitabine-Induced Apoptosis by Restoration of p53 Function in Human Pancreatic Tumors. Oncology, 2005, 68, 179-189.	1.9	18
274	Organochlorine Exposure and Colorectal Cancer Risk. Environmental Health Perspectives, 2004, 112, 1460-1466.	6.0	69
275	A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene, 2004, 23, 1954-1956.	5.9	188
276	p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combinedâ€modality approach. Cancer, 2004, 100, 1859-1867.	4.1	60
277	Genetic evolution in colon cancer KM12 cells and metastatic derivates. International Journal of Cancer, 2004, 110, 869-874.	5.1	31
278	Colorectal cancer risk and theAPC D1822V variant. International Journal of Cancer, 2004, 112, 161-163.	5.1	15
279	Standardized approach for microsatellite instability detection in gastric carcinomas. Human Pathology, 2004, 35, 335-342.	2.0	11
280	Orthotopic Implantation of Human Hepatocellular Carcinoma in Mice. Clinical Cancer Research, 2004, 10, 2150-2157.	7.0	25
281	Genomic Instability, DNA Repair Pathways, and Cancer. , 2004, , 491-504.		0
282	Orthotopic implantation of human hepatocellular carcinoma in mice. Establishment of the BCLC-9 cell line. Journal of Hepatology, 2003, 38, 89.	3.7	0
283	Expression of Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein 1, Breast Cancer Resistance Protein and Lung Resistance Related Protein in Locally Advanced Bladder Cancer Treated With Neoadjuvant Chemotherapy: Biological and Clinical Implications. Journal of Urology, 2003, 170, 1383-1387.	0.4	67
284	Clinical Usefulness of Virulence Factors of Helicobacter pylori as Predictors of the Outcomes of Infection. What is the Evidence?. Scandinavian Journal of Gastroenterology, 2003, 38, 905-915.	1.5	7
285	The structural nature of chromosomal instability in colon cancer cells. FASEB Journal, 2003, 17, 289-291.	0.5	29
286	Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Research, 2003, 63, 3560-6.	0.9	244
287	Common genetic evolutionary pathways in familial adenomatous polyposis tumors. Cancer Research, 2003, 63, 5731-7.	0.9	11
288	Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer. Cancer Research, 2003, 63, 7206-14.	0.9	41

#	Article	IF	Citations
289	Codon 12 and codon 13 mutations at the Kâ€ras gene induce different soft tissue sarcoma types in nude mice. FASEB Journal, 2002, 16, 1642-1644.	0.5	34
290	Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model. FASEB Journal, 2002, 16, 975-982.	0.5	19
291	Mismatch repair gene analysis in Catalonian families with colorectal cancer. Journal of Medical Genetics, 2002, 39, 29e-29.	3.2	6
292	Treatment with 5-fluorouracil enhances radiosensitivity of the human pancreatic cancer cell line MiaPaCa-2. Pancreatology, 2002, 2, 40-45.	1.1	8
293	Genetic susceptibility and gastric cancer risk. International Journal of Cancer, 2002, 100, 249-260.	5.1	277
294	Effect of cholecystokinin-A receptor blockade on postprandial insulinaemia and gastric emptying in humans. Neurogastroenterology and Motility, 2002, 14, 519-525.	3.0	15
295	Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism. Gastroenterology, 2001, 120, 200-209.	1.3	21
296	p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis. Gastrointestinal Endoscopy, 2001, 53, 734-743.	1.0	48
297	Clinical usefulness of K-ras gene mutation detection and cytology in pancreatic juice in the diagnosis and screening of pancreatic cancer. European Journal of Gastroenterology and Hepatology, 2001, 13, 1153-1159.	1.6	43
298	Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 581-590.	2.8	26
299	Redefining the Significance of Aneuploidy in the Prognostic Assessment of Colorectal Cancer. Laboratory Investigation, 2001, 81, 307-315.	3.7	25
300	Genetic Evolution in the Metastatic Progression of Human Pancreatic Cancer Studied by CGH. Laboratory Investigation, 2001, 81, 1703-1707.	3.7	11
301	DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Human Molecular Genetics, 2001, 10, 3001-3007.	2.9	374
302	A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. International Journal of Cancer, 2000, 85, 73-77.	5.1	43
303	DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene, 2000, 19, 546-555.	5.9	55
304	DNA Copy Number Changes and Evaluation of MYC, IGF1R, and FES Amplification in Xenografts of Pancreatic Adenocarcinoma. Cancer Genetics and Cytogenetics, 2000, 116, 133-141.	1.0	56
305	Intron splice acceptor site polymorphism in the hMSH2 gene in sporadic and familial colorectal cancer. British Journal of Cancer, 2000, 82, 535-537.	6.4	14
306	Standardized Approach for Microsatellite Instability Detection in Colorectal Carcinomas. Journal of the National Cancer Institute, 2000, 92, 544-549.	6.3	75

#	Article	IF	Citations
307	Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer. European Journal of Cancer, 2000, 36, 2069-2075.	2.8	19
308	Transcription of sst2 somatostatin receptor gene is altered by promoter polymorpidsm in human pancreatic cancer cells. Gastroenterology, 2000, 118, A711.	1.3	0
309	What is the hereditary non-polyposis colorectal cancer syndrome?. , 2000, 2, 191-201.		1
310	p53 and K-ras Gene Mutations Correlate With Tumor Aggressiveness But Are Not of Routine Prognostic Value in Colorectal Cancer. Journal of Clinical Oncology, 1999, 17, 1375-1375.	1.6	133
311	Orthotopic Models of Human Pancreatic Cancer. Annals of the New York Academy of Sciences, 1999, 880, 103-109.	3.8	48
312	Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells. Cancer Gene Therapy, 1999, 6, 428-436.	4.6	24
313	Overall deregulation in gene expression as a novel indicator of tumor aggressiveness in colorectal cancer. Oncogene, 1999, 18, 4383-4387.	5.9	5
314	Restriction fragment length polymorphism of the L-myc gene is not a prognostic factor in bladder cancer patients. British Journal of Cancer, 1999, 79, 1855-1858.	6.4	13
315	K-ras Mutations in DNA Extracted From the Plasma of Patients With Pancreatic Carcinoma: Diagnostic Utility and Prognostic Significance. Journal of Clinical Oncology, 1999, 17, 578-578.	1.6	206
316	Disruption of the antiproliferative TGF-Î² signaling pathways in human pancreatic cancer cells. Oncogene, 1998, 17, 1969-1978.	5.9	181
317	Intron splice acceptor site polymorphism in the human MSH2 gene in ulcerative colitis. Gastroenterology, 1998, 114, A1057.	1.3	0
318	Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. Gastroenterology, 1996, 110, 1587-1594.	1.3	59
319	Ras Oncogene Mutations in Thyroid Tumors. Diagnostic Molecular Pathology, 1996, 5, 45-52.	2.1	65
320	Pancreatic cancer in europe: Ki-ras gene mutation pattern shows geographical differences. International Journal of Cancer, 1994, 57, 167-171.	5.1	72
321	Expression of somatostatin in rat pineal cells in culture. Journal of Pineal Research, 1993, 15, 43-45.	7.4	15
322	Genetic Heterogeneity of the c-K-ras Locus in Colorectal Adenomas but not in Adenocarcinomas. Journal of the National Cancer Institute, 1993, 85, 1058-1063.	6.3	137
323	Experimental study of the efficacy of the endoluminal prosthesis in colonic anastomoses. International Journal of Colorectal Disease, 1992, 7, 21-25.	2.2	9
324	Frequency and Spectrum of Mutations at Codons 12 and 13 of the C-K-ras Gene in Human Tumors. Environmental Health Perspectives, 1991, 93, 125.	6.0	8

#	Article	IF	Citations
325	Mutational activation of the c-K-ras gene in human pancreatic carcinoma. Bailliere's Clinical Gastroenterology, 1990, 4, 151-169.	0.9	49